COVID-19 drug repurposing research
|Part of a series on the|
Drug repositioning (also known as drug repurposing, re-profiling, re-tasking, or therapeutic switching) is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed. This is one line of scientific research which is being pursued to develop safe and effective COVID-19 treatments. Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.
Several existing antiviral medications, previously developed or used as treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), HIV/AIDS, and malaria, have been researched as potential COVID‑19 treatments, with some moving into clinical trials.
In a statement to the journal Nature Biotechnology in February 2020, US National Institutes of Health Viral Ecology Unit chief Vincent Munster said, "The general genomic layout and the general replication kinetics and the biology of the MERS, SARS and [SARS-CoV-2] viruses are very similar, so testing drugs which target relatively generic parts of these coronaviruses is a logical step".
Outbreaks of novel emerging infections such as COVID-19 pose unique challenges to discover treatments appropriate for clinical use, given the small amount of time available for drug discovery. Since the process of developing and licensing a new drug for COVID-19 was expected to pose a particularly long delay, researchers have been probing the existing compendium of approved antivirals and other drugs as a cost-effective strategy in the meantime.
One approach used in repositioning is to look for drugs that act through virus-related targets such as the RNA genome (i.e. remdesivir). Another approach concerns drugs acting through polypeptide packing (i.e. lopinavir).
Monoclonal antibodies under investigation for repurposing include anti-IL-6 agents (tocilizumab) and anti-IL-8 (BMS-986253). (This is in parallel to novel monoclonal antibody drugs developed specifically for COVID-19.)
Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R). It has been studied to see if it can improve the prognosis for patients with COVID-19 pneumonia and systemic hyperinflammation. One small study indicated some beneficial effects of treatment with mavrilimumab compared with those who were not.
In January 2021, the UK National Health Service issued guidance that the immune modulating drugs tocilizumab and sarilumab were beneficial when given promptly to people with COVID-19 admitted to intensive care, following research which found a reduction in the risk of death by 24%.
Tocilizumab is an interleukin 6 inhibitor authorized for use in several conditions, including rheumatoid arthritis, giant cell arteritis, systemic juvenile idiopathic arthritis and severe cytokine release syndrome. Its use has been studied in a number of trials.
Hoffmann–La Roche and the WHO have run separate trials in severe cases. Roche announced on July 29, 2020, that its randomized double-blind trial of tocilizumab for the treatment of pneumonia in Covid patients had shown no benefits.
The REMAP‑CAP study in the UK found that tocilizumab was beneficial in adults with severe COVID‑19, who were critically ill and receiving respiratory or cardiovascular organ support in an intensive care setting, when this was started within 24 hours of the need for organ support. The use of tocilizumab and its place in therapy have been updated by UK NICE in January 2021.
It has been part of the large RECOVERY Trial in the UK. The published results have been reviewed as the most definitive evidence addressing the controversy over whether tocilizumab should be included in treatment for severely ill patients with COVID-19. Over 4000 adults were randomly assigned to tocilizumab or usual care, several times more than the total in previous randomised trials, and most patients received systemic corticosteroids. Mortality within 28 days was 31% in patients allocated to tocilizumab and 35% in those receiving usual care (rate ratio 0·85; p=0·0028). Discharge from the hospital within 28 days was also more likely.
In June 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for tocilizumab for the treatment of COVID-19 in hospitalized people aged two years of age and older who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
As of August 2021[update], the European Medicines Agency (EMA) is evaluating tocilizumab to extend its use to include treatment of hospitalized adults with severe COVID-19 who are already receiving treatment with corticosteroids and require extra oxygen or mechanical ventilation (breathing assisted by a machine).
Research is focused on repurposing approved antiviral drugs that have been previously developed against other viruses, such as MERS-CoV, SARS-CoV, and West Nile virus. These include favipiravir, remdesivir, ribavirin, triazavirin, and umifenovir.
The combination of artesunate/pyronaridine was found to have an inhibitory effect on SARS-CoV-2 in vitro tests using Hela cells. Artesunate/pyronaridine showed a virus titer inhibition rate of 99% or more after 24 hours, while cytotoxicity was also reduced. A preprint published in July 2020, reported that pyronaridine and artesunate exhibit antiviral activity against SARS-CoV-2 and influenza viruses using human lung epithelial (Calu-3) cells. It is in phase II clinical trial in South Korea and in South Africa.
GS-441524 is the nucleoside of the ProTide remdesivir. It has been shown to cure cats infected with Feline infectious peritonitis (FIP), a feline form of coronavirus with a 96% cure rate. Studies have shown that even when remdesivir is administered, GS-441524 is the predominant metabolite circulating in serum due to rapid hydrolysis of the remdesivir pro-drugs, followed by dephosphorylation.[unreliable medical source?] Some researchers have suggested its utility as a treatment for COVID‑19, noting easier synthesis, lack of first-pass metabolism in the liver, greater hydrophilicity and triphosphate formation in cell types irrespective of expression CES1 and CTSA, the enzymes required to bioactivate remdesivir.
Molnupiravir is a drug developed to treat influenza. It is in Phase III trials as a treatment for COVID-19. In December 2020, scientists reported that the antiviral drug molnupiravir developed for the treatment of influenza can completely suppress SARS-CoV-2 transmission within 24 hours in ferrets whose COVID-19 transmission they find to closely resemble SARS-CoV-2 spread in human young-adult populations. A clinical trial, which has not as of 1 October 2021 been peer reviewed, suggests molnupiravir taken orally can reduce the risk of hospitalization and prevent death in patients diagnosed with COVID-19. The drug needs to be given early to be effective.
Coronaviruses species possess an intrinsic resistance to ribavirin.
Favipiravir is an antiviral drug approved for the treatment of influenza in Japan. There is limited evidence suggesting that, compared to other antiviral drugs, favipiravir might improve outcomes for people with COVID-19, but more rigorous studies are needed before any conclusions can be drawn.
Chinese clinical trials in Wuhan and Shenzhen claimed to show that favipiravir was "clearly effective". Of 35 patients in Shenzhen tested negative in a median of 4 days, while the length of illness was 11 days in the 45 patients who did not receive it. In a study conducted in Wuhan on 240 patients with pneumonia half were given favipiravir and half received umifenovir. The researchers found that patients recovered from coughs and fevers faster when treated with favipiravir, but that there was no change in how many patients in each group progressed to more advanced stages of illness that required treatment with a ventilator.
On 22 March 2020, Italy approved the drug for experimental use against COVID‑19 and began conducting trials in the three regions most affected by the disease. The Italian Pharmaceutical Agency reminded the public that the existing evidence in support of the drug is scant and preliminary.
On 26 May 2021, a systematic review found a 24% greater chance of clinical improvement when administered in the first seven days of hospitalization, but no statistically significant reduction in mortality for any of the groups, including hospitalized patients and those with mild or moderate symptoms.
In March 2020, the main protease (3CLpro) of the SARS-CoV-2 virus was identified as a target for post-infection drugs. The enzyme is essential for processing the replication-related polyprotein. To find the enzyme, scientists used the genome published by Chinese researchers in January 2020 to isolate the main protease. Protease inhibitors approved for treating human immunodeficiency viruses (HIV) – lopinavir and ritonavir – have preliminary evidence of activity against the coronaviruses, SARS and MERS. As a potential combination therapy, they are used together in two Phase III arms of the 2020 global Solidarity project on COVID‑19. A preliminary study in China of combined lopinavir and ritonavir found no effect in people hospitalized for COVID‑19.
One study of lopinavir/ritonavir (Kaletra), a combination of the antivirals lopinavir and ritonavir, concluded that "no benefit was observed". The drugs were designed to inhibit HIV from replicating by binding to the protease. A team of researchers at the University of Colorado are trying to modify the drugs to find a compound that will bind with the protease of SARS-CoV-2. There are criticisms within the scientific community about directing resources to repurposing drugs specifically developed for HIV/AIDS because such drugs are unlikely to be effective against a virus lacking the specific HIV-1 protease they target. The WHO included lopinavir/ritonavir in the international Solidarity trial.
On 29 June, the chief investigators of the UK RECOVERY Trial reported that there was no clinical benefit from use of lopinavir-ritonavir in 1,596 people hospitalized with severe COVID-19 infection over 28 days of treatment.
A study published in October 2020, screening those FDA approved drugs which target SARS-CoV-2 spike (S) protein proposed that the current unbalanced combination formula of lopinavir might in fact interfere with the ritonavir's blocking activity on the receptor binding domain-human angiotensin converting enzyme-2 (RBD-hACE2) interaction, thus effectively limiting its therapeutic benefit in COVID-19 cases.
Remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. During the COVID-19 pandemic, remdesivir was approved or authorized for emergency use to treat COVID‑19 in around 50 countries. Updated guidelines from the World Health Organization in November 2020 include a conditional recommendation against the use of remdesivir for the treatment of COVID-19.
Remdesivir was originally developed to treat hepatitis C, and was subsequently investigated for Ebola virus disease and Marburg virus infections before being studied as a post-infection treatment for COVID-19.
The most common side effect in healthy volunteers is raised blood levels of liver enzymes (a sign of liver problems). The most common side effect in people with COVID‑19 is nausea. Side effects may include liver inflammation and an infusion-related reaction with nausea, low blood pressure, and sweating.
Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
The idea of repurposing host-directed drugs for antiviral therapy has experienced a renaissance. In some cases the research has highlighted fundamental limitations to their use for the treatment of acute RNA virus infections. Antiparasitics that have been investigated include chloroquine, hydroxychloroquine, mefloquine, ivermectin, and atovaquone.
Chloroquine and hydroxychloroquine
Chloroquine and hydroxychloroquine are anti-malarial medications also used against some auto-immune diseases. Chloroquine, along with hydroxychloroquine, was an early failed experimental treatment for COVID-19. They are not effective for preventing infection.
Several countries initially used chloroquine or hydroxychloroquine for treatment of persons hospitalized with COVID‑19 (as of March 2020), though the drug was not formally approved through clinical trials. From April to June 2020, there was an emergency use authorization for their use in the United States, and was used off label for potential treatment of the disease. On 24 April 2020, citing the risk of "serious heart rhythm problems", the FDA posted a caution against using the drug for COVID‑19 "outside of the hospital setting or a clinical trial".
Their use was withdrawn as a possible treatment for COVID‑19 infection when it proved to have no benefit for hospitalized patients with severe COVID-19 illness in the international Solidarity trial and UK RECOVERY Trial. On 15 June, the FDA revoked its emergency use authorization, stating that it was "no longer reasonable to believe" that the drug was effective against COVID-19 or that its benefits outweighed "known and potential risks". In fall of 2020, the National Institutes of Health issued treatment guidelines recommending against the use of hydroxychloroquine for COVID-19 except as part of a clinical trial.In 2021, hydroxychloroquine was part of the recommended treatment for mild cases in India.
In vitro, ivermectin has antiviral effects against several distinct positive-sense single-strand RNA viruses, including SARS-CoV-2. Subsequent studies found that ivermectin could inhibit replication of SARS-CoV-2 in monkey kidney cell culture with an IC50 of 2.2–2.8 μM. Based on this information, however, doses much higher than the maximum approved or safely achievable for use in humans would be required for an antiviral effect. Aside from practical difficulties, such high doses are not covered by current human-use approvals of the drug and would be toxic, as the antiviral mechanism of action is considered to operate by the suppression of a host cellular process, specifically the inhibition of nuclear transport by importin α/β1. Self-medication with a highly concentrated formula intended for horses has led to reports of hospitalizations, and two deaths, possibly due to interaction with other medications. To resolve uncertainties from previous small or poor-quality studies, as of June 2021[update], large scale trials are underway in the United States and the United Kingdom.
Many studies on ivermectin for COVID-19 have serious methodological limitations, resulting in very low evidence certainty. Several publications that supported the efficacy of ivermectin for COVID-19 have been retracted due to errors, unverifiable data and ethical concerns, including misleading "meta-analysis" websites with substandard methods. As a result, several organizations have publicly expressed that there is insufficient evidence of effectiveness at preventing or treating COVID-19 and advised against the use of the drug for unapproved purposes. In February 2021, Merck, the developer of the drug, issued a statement saying that there is no good evidence ivermectin is effective against COVID-19, and that attempting such use may be unsafe. After reviewing the evidence on ivermectin, the European Medicines Agency (EMA) advised against its use for prevention or treatment of COVID-19 and that "the available data do not support its use for COVID-19 outside well-designed clinical trials." The U.S. National Institutes of Health COVID-19 Treatment Guidelines state that there is insufficient evidence for ivermectin to allow for a recommendation for or against its use. In the United Kingdom, the national COVID-19 Therapeutics Advisory Panel determined that the evidence base and plausibility of ivermectin as a COVID-19 treatment were insufficient to pursue further investigations. Ivermectin is not approved by the U.S. Food and Drug Administration (FDA) for use in treating any viral illness and is not authorized for use to treat COVID-19 within the European Union. The WHO also said that ivermectin should not be used to treat COVID-19 except in a clinical trial. The Brazilian Health Regulatory Agency, Brazilian Society of Infectious Diseases, and Brazilian Thoracic Society issued position statements advising against the use of ivermectin for prevention or treatment of early-stage COVID-19.
Misinformation, lower degrees of trust, and a sense of despair over increasing case and death counts have led to an increase in ivermectin's use in Central and Eastern Europe, Latin America, and South Africa. A black market has also developed in many of these countries where official approval has not been granted.
The viral social media misinformation about ivermectin has gained particular attention in South Africa where an anti-vaccination group called "South Africa Has A Right To Ivermectin" has been lobbying for the drug to be made available for prescription. Another group, the "Ivermectin Interest Group" launched a court case against the South African Health Products Regulatory Authority (SAHPRA), and as a result a compassionate use exemption was granted. SAPHRA stated in April 2021 that "At present, there are no approved treatments for COVID-19 infections."
Despite the absence of high-quality evidence to suggest any efficacy and advice to the contrary, some governments have allowed its off-label use for prevention and treatment of COVID-19. Countries that have granted such official approval for ivermectin include the Czech Republic, Slovakia, Mexico, Peru (later rescinded), and India (later rescinded).
Medications to prevent blood clotting have been suggested for treatment, and anticoagulant therapy with low-molecular-weight heparin appears to be associated with better outcomes in severe COVID‐19 showing signs of coagulopathy (elevated D-dimer). Several anticoagulants have been tested in Italy, with low-molecular-weight heparin being widely used to treat patients, prompting the Italian Medicines Agency to publish guidelines on its use.
As of July 2021[update], the European Medicines Agency (EMA) is evaluating an application to extend the use of anakinra (Kineret) to include treatment of COVID-19 in adults with pneumonia who are at risk of developing severe respiratory failure (inability of the lungs to work properly).
IFN-β 1b have been shown in an open label randomised controlled trial in combination with lopinavir/ ritonavir and ribavirin to significantly reduce viral load, alleviate symptoms and reduce cytokine responses when compared to lopinavir/ ritonavir alone.<Lancet 2020;395(10238):1695-1704> IFN-β will be included in the international Solidarity Trial in combination with the HIV drugs Lopinavir and Ritonavir. as well as the REMAP-CAP Finnish biotech firm Faron Pharmaceuticals continues to develop INF-beta for ARDS and is involved in worldwide initiatives[which?] against COVID‑19, including the Solidarity trial. UK biotech firm Synairgen started conducting trials on IFN-β, a drug that was originally developed to treat COPD.
Dexamethasone is a corticosteroid medication in use for multiple conditions such as rheumatic problems, skin diseases, asthma and chronic obstructive lung disease among others. A multi-center, randomized controlled trial of dexamethasone in treating acute respiratory distress syndrome (ARDS), published in February 2020, showed reduced need for mechanical ventilation and mortality. Dexamethasone is only helpful in people requiring supplemental oxygen. Following an analysis of seven randomized trials, the WHO recommends the use of systemic corticosteroids in guidelines for treatment of people with severe or critical illness, and that they not be used in people that do not meet the criteria for severe illness.
On 16 June, the Oxford University RECOVERY Trial issued a press release announcing preliminary results that the drug could reduce deaths by about a third in participants on ventilators and by about a fifth in participants on oxygen; it did not benefit patients who did not require respiratory support. The researchers estimated that treating 8 patients on ventilators with dexamethasone saved one life, and treating 25 patients on oxygen saved one life. Several experts called for the full dataset to be published quickly to allow wider analysis of the results. A preprint was published on June 22 and the peer-reviewed article appeared on July 17.
Based on those preliminary results, dexamethasone treatment has been recommended by the US National Institutes of Health (NIH) for patients with COVID-19 who are mechanically ventilated or who require supplemental oxygen but are not mechanically ventilated. The NIH recommends against using dexamethasone in patients with COVID-19 who do not require supplemental oxygen. In July 2020, the World Health Organization (WHO) stated they are in the process of updating treatment guidelines to include dexamethasone or other steroids.
The Infectious Diseases Society of America (IDSA) guideline panel suggests the use of glucocorticoids for patients with severe COVID-19; where severe is defined as patients with oxygen saturation (SpO2) ≤94% on room air, and those who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The IDSA recommends against the use of glucocorticoids for those with COVID-19 without hypoxemia requiring supplemental oxygen.
In July 2020, the European Medicines Agency (EMA) started reviewing results from the RECOVERY study arm that involved the use of dexamethasone in the treatment of patients with COVID-19 admitted to the hospital to provide an opinion on the results. It focused particularly on the potential use of the drug for the treatment of adults with COVID-19.
In September 2020, the WHO released updated guidance on using corticosteroids for COVID-19. The WHO recommends systemic corticosteroids rather than no systemic corticosteroids for the treatment of people with severe and critical COVID-19 (strong recommendation, based on moderate certainty evidence). The WHO suggests not to use corticosteroids in the treatment of people with non-severe COVID-19 (conditional recommendation, based on low certainty evidence).
In September 2020, the European Medicines Agency (EMA) endorsed the use of dexamethasone in adults and adolescents (from twelve years of age and weighing at least 40 kilograms (88 lb)) who require supplemental oxygen therapy. Dexamethasone can be taken by mouth or given as an injection or infusion (drip) into a vein.
In September 2020, a meta-analysis published by the WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group found hydrocortisone to be effective in reducing mortality rate of critically ill COVID-19 patients when compared to other usual care or a placebo.
The use of corticosteroids can cause a severe and deadly "hyperinfection" syndrome for people with strongyloidiasis, which may be an underlying condition in populations exposed to the parasite Strongyloides stercoralis. This risk can be mitigated by the presumptive use of ivermectin before steroid treatment.
Administration of this inhaled steroid early in the course of COVID-19 infection has been found to reduce the likelihood of needing urgent medical care and reduced the time to recovery. More studies are on-going. In April 2021, budesonide was approved by authorities in the UK for off-label use to treat COVID-19 on a case-by-case basis.
Ciclesonide, an inhaled corticosteroid for asthma, was identified as a candidate antiviral in an in vitro drug screening assay done in South Korea. It has been used for treatment of pre-symptomatic COVID-19 patients and is under-going clinical trials.
Supplementation with micronutrients, including vitamin C, has been suggested as part of the supportive management of COVID-19, as levels of vitamin C in serum and leukocytes are depleted in the acute stage of infection owing to increased metabolic demands. The use of high-dose intravenous vitamin C has been studied. According to ClinicalTrials.gov, there are at least 34 ongoing clinical trials including vitamin C, which have completed or are recruiting people, hospitalized and severely ill with COVID‑19.
During the COVID-19 pandemic, there has been interest in vitamin D status and supplements, given the significant overlap in the risk factors for severe COVID-19 and vitamin D deficiency. These include obesity, older age, and Black or Asian ethnic origin, and it is notable that vitamin D deficiency is particularly common within these groups.
The National Institutes of Health (NIH) COVID-19 Treatment Guidelines stated in July 2020 that "there are insufficient data to recommend either for or against the use of vitamin D for the prevention or treatment of COVID-19."
The general recommendation to consider taking vitamin D supplements, particularly given the levels of vitamin D deficiency in Western populations, has been repeated. As of February 2021[update], the English National Institute for Health and Care Excellence (NICE) continued to recommend small doses of supplementary vitamin D for people with little exposure to sunshine, but recommended that practitioners should not offer a vitamin D supplement solely to prevent or treat COVID‑19, except as part of a clinical trial.
Multiple studies have reported links between pre-existing vitamin D deficiency and the severity of the disease. Several systematic reviews and meta-analyses of these show that vitamin D deficiency may be associated with a higher probability of becoming infected with COVID-19, and have clearly demonstrated there are significant associations between deficiency and a greater severity of the disease, including relative increases in hospitalization and mortality rates of about 80%. The quality of some of the studies included and whether this demonstrates a causal relationship has been questioned.
Many clinical trials are underway or have been completed assessing the use of oral vitamin D and its metabolites such as calcifediol for prevention or treatment of COVID‑19 infection, especially in people with vitamin D deficiency.
The effects of oral vitamin D supplementation on the need for intensive care unit (ICU) admission and mortality in hospitalized COVID-19 patients has been the subject of a meta-analysis. A much lower ICU admission rate was found in patients who received vitamin D supplementation, which was only 36% of that seen in patients without supplementation (p<0.0001). No significant effects on mortality were found in this meta-analysis. The certainty of these analyses is limited by the heterogenicity in the studies which include both vitamin D3 (cholecalciferol) and calcifediol, but these findings indicate a potential role in improving COVID-19 severity, with more robust data being required to substantiate any effects on mortality.
Calcifediol, which is 25-hydroxyvitamin D, is more quickly activated, and has been used in several trials. Review of the published results suggests that calcifediol supplementation may have a protective effect on the risk of ICU admissions in COVID-19 patients.
A form of angiotensin-converting enzyme 2, a Phase II trial is underway with 200 patients to be recruited from severe, hospitalized cases in Denmark, Germany, and Austria to determine the effectiveness of the treatment.
Some antibiotics that have been identified as potentially repurposable as COVID‑19 treatments, including teicoplanin, oritavancin, dalbavancin, monensin, and azithromycin. New York State began trials for the antibiotic azithromycin on 24 March 2020.
On 31 July 2020, the U.S. Food and Drug Administration (FDA) authorized Revive Therapeutics to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase III clinical trial protocol to evaluate the safety and efficacy of the antirheumatic agent bucillamine in patients with mild-moderate COVID-19.
The oral JAK inhibitor baricitinib is also being studied for COVID-19 treatment. In November 2020, the FDA granted emergency use authorization for baricitinib to be given to certain people hospitalized with suspected or confirmed COVID-19 (specifically, adults and children two years of age or older requiring supplemental oxygen, mechanical ventilation, or ECMO), but only in conjunction with remdesivir. In a single clinical trial, this combination therapy was shown to have a small, but statistically significant effect on patient outcomes compared to administration of remdesivir alone. In April 2021, the European Medicines Agency (EMA) started evaluating the extended use of baricitinib to include treatment of COVID-19 in hospitalized patients ten years of age and older who require supplemental oxygen. In July 2021, the FDA revised the EUA for baricitinib now authorizing it alone for the treatment of COVID-19 in hospitalized people aged two years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Under the revised EUA, baricitinib is no longer required to be administered with remdesivir.
In 2021, the importance of drug repurposing for COVID-19 led to the establishment of broad-spectrum therapeutics. Broad-spectrum therapeutics are effective against multiple types of pathogens. Such drugs have been suggested as potential emergency treatments for future pandemics.
Histamine H2 receptor antagonists are under investigation. Cimetidine has been suggested as a treatment for COVID-19. Famotidine has been suggested as a treatment for COVID-19, and a clinical study is underway.
Researchers from the Montreal Heart Institute in Canada are studying the role of colchicine in reducing inflammation and pulmonary complications in patients suffering from mild symptoms of COVID‑19. The study, named COLCORONA, was recruiting 6000 adults 40 and older who were diagnosed with COVID‑19 and experienced mild symptoms not requiring hospitalization. Women who were pregnant or breastfeeding or who did not have an effective contraceptive method were not eligible. The trail results are favorable, but inconclusive.
Fenofibrate and bezafibrate have been suggested for treatment of life-threatening symptoms of COVID-19. Fenofibrate also lowered severe progressive inflammation markers in hospitalized COVID-19 patients within 48 hours of treatment in an Israeli study. It showed extremely promising results by interfering with how coronavirus reproduce.
A trial called "Liberate" has been started in the United Kingdom to determine the effectiveness of ibuprofen in reducing the severity and progression of lung injury which results in breathing difficulties for COVID‑19 patients. Subjects are to receive three doses of a special formulation of the drug – lipid ibuprofen – in addition to usual care.
A clinical cohort study in Brazil found that COVID-19 patients who received a recent influenza vaccine needed less intensive care support, less invasive respiratory support, and were less likely to die.[unreliable medical source?]
nanoFenretinide is nanoparticle sized fenretinide and repurposed oncology drug approved to enter the clinic for a lymphoma indication. It was identified as a candidate antiviral in an in vitro drug screening assay done in South Korea. Fenretinide's clinical safety profile also makes it an ideal candidate in combination regimens.
- "Repurposing Drugs". National Center for Advancing Translational Sciences (NCATS). U.S. Department of Health & Human Services, National Institutes of Health. 7 November 2017. Retrieved 26 March 2020.
- Harrison C (April 2020). "Coronavirus puts drug repurposing on the fast track". Nature Biotechnology. 38 (4): 379–81. doi:10.1038/d41587-020-00003-1. PMID 32205870. S2CID 213394680.
- Sleigh SH, Barton CL (2010). "Repurposing Strategies for Therapeutics". Pharmaceutical Medicine. 24 (3): 151–59. doi:10.1007/BF03256811. S2CID 25267555.
- "COVID-19 Vaccine Frontrunners".
- Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. (April 2020). "Effectiveness of convalescent plasma therapy in severe COVID-19 patients". Proceedings of the National Academy of Sciences of the United States of America. 117 (17): 9490–96. doi:10.1073/pnas.2004168117. PMC 7196837. PMID 32253318.
- Li G, De Clercq E (March 2020). "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)". Nature Reviews. Drug Discovery. 19 (3): 149–50. doi:10.1038/d41573-020-00016-0. PMID 32127666.
- "COVID-19 treatment and vaccines tracker (Choose tab of interest, apply filters to view select data)". Milken Institute. 2 June 2020. Retrieved 3 June 2020. Lay summary.
- Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (April 2020). "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review". JAMA. 323 (18): 1824–36. doi:10.1001/jama.2020.6019. PMID 32282022.
- Singh, Thakur Uttam; Parida, Subhashree; Lingaraju, Madhu Cholenahalli; Kesavan, Manickam; Kumar, Dinesh; Singh, Raj Kumar (December 2020). "Drug repurposing approach to fight COVID-19". Pharmacological Reports. 72 (6): 1479–1508. doi:10.1007/s43440-020-00155-6. PMC 7474498. PMID 32889701.
- "RECOVERY Trial". Retrieved 17 June 2020.
- "Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19". ClinicalTrials.gov. Retrieved 10 September 2020.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab" (PDF). American Medical Association. Archived from the original (PDF) on 28 September 2012.
- Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F (September 2011). "Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study". Annals of the Rheumatic Diseases. 70 (9): 1542–49. doi:10.1136/ard.2010.146225. PMC 3147227. PMID 21613310.
- De Luca G, Cavalli G, Campochiaro C, Della-Torre E, Angelillo P, Tomelleri A, et al. (16 June 2020). "GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study". The Lancet Rheumatology. 2 (8): e465–73. doi:10.1016/S2665-9913(20)30170-3. PMC 7430344. PMID 32835256.
- "Arthritis drugs effective in improving survival in sickest COVID-19 patients". National Institute of Health Research. 7 January 2021.
- "Product overview | COVID-19 rapid evidence summary: Tocilizumab for COVID-19 | Advice | NICE". Retrieved 20 January 2021.
- "WHO and Roche launch trials of potential coronavirus treatments". SwissInfo.Ch. 20 March 2020. Retrieved 8 August 2020.
- "Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia". Roche (Press release). 29 July 2020. Retrieved 18 August 2020.
- Gupta S, Leaf DE (May 2021). "Tocilizumab in COVID-19: some clarity amid controversy". Lancet. 397 (10285): 1599–1601. doi:10.1016/S0140-6736(21)00712-1. PMC 8084409. PMID 33933194.
- "Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 24 June 2021. Retrieved 24 June 2021. This article incorporates text from this source, which is in the public domain.
- "Tocilizumab Emergency Use Authorization (EUA)" (PDF). U.S. Food and Drug Administration (FDA). June 2021. This article incorporates text from this source, which is in the public domain.
- "Frequently Asked Questions on the Emergency Use Authorization for Actemra (tocilizumab) for Treatment of COVID-19" (PDF). U.S. Food and Drug Administration (FDA). July 2021. This article incorporates text from this source, which is in the public domain.
- "EMA starts evaluating use of RoActemra in hospitalised adults with severe COVID-19". European Medicines Agency (EMA) (Press release). 16 August 2021. Retrieved 24 August 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- Dong L, Hu S, Gao J (2020). "Discovering drugs to treat coronavirus disease 2019 (COVID-19)". Drug Discoveries & Therapeutics. 14 (1): 58–60. doi:10.5582/ddt.2020.01012. PMID 32147628.
- Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. (May 2020). "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial". Lancet. 395 (10236): 1569–78. doi:10.1016/S0140-6736(20)31022-9. PMC 7190303. PMID 32423584.
- Lu CC, Chen MY, Lee WS, Chang YL (2020). "Potential therapeutic agents against COVID-19: What we know so far". J Chin Med Assoc. 83 (6): 534–36. doi:10.1097/JCMA.0000000000000318. PMC 7176266. PMID 32243270.
- Wu X, Yu K, Wang Y, Xu W, Ma H, Hou Y, Li Y, Cai B, Zhu L, Zhang M, Hu X, Gao J, Wang Y, Qin H, Zhao M, Zhang Y, Li K, Du Z, Yang B (3 July 2020). "The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol". Engineering (Beijing). 6 (10): 1199–204. doi:10.1016/j.eng.2020.06.011. PMC 7332434. PMID 32837750.
- Lu H (March 2020). "Drug treatment options for the 2019-new coronavirus (2019-nCoV)". Bioscience Trends. 14 (1): 69–71. doi:10.5582/bst.2020.01020. PMID 31996494.
- "'Pyramax' drug repurposing?... targets COVID-19 treatment". Doctor's News. Retrieved 25 June 2020.
- Bae JY, Lee GE, Park H, Cho J, Kim YE, Lee JY, Ju C, Kim WK, Kim JI, Park MS (2020). "Pyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza". bioRxiv. doi:10.1101/2020.07.28.225102. S2CID 220885187.
- "COVID-19: Pyramax Enters Phase II Clinical Trial in South Korea". www.pharmanewsonline.com. Retrieved 17 June 2020.
- "A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase II Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients". nedrug.mfds.go.kr. Retrieved 25 June 2020.
- "The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients". ClinicalTrials.gov. Retrieved 10 September 2020.
- "COVID-19 Treatment in South Africa". ClinicalTrials.gov. Retrieved 21 September 2020.
- Zhang S (8 May 2020). "A Much-Hyped COVID-19 Drug Is Almost Identical to a Black-Market Cat Cure". The Atlantic.
- Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, Liu H (April 2019). "Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis". Journal of Feline Medicine and Surgery. 21 (4): 271–81. doi:10.1177/1098612X19825701. PMC 6435921. PMID 30755068.
- Yan VC, Muller FL (July 2020). "Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment". ACS Medicinal Chemistry Letters. 11 (7): 1361–66. doi:10.1021/acsmedchemlett.0c00316. PMC 7315846. PMID 32665809.
- Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (March 2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–85. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMC 5551389. PMID 26934220.
- Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. (June 2017). "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses". Science Translational Medicine. 9 (396): eaal3653. doi:10.1126/scitranslmed.aal3653. PMC 5567817. PMID 28659436.
- Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. (April 2020). "Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2". bioRxiv: 2020.04.15.043166. doi:10.1101/2020.04.15.043166. PMC 7239049. PMID 32511319.
- "Gilead should ditch remdesivir and focus on its simpler ancestor". Stat. 14 May 2020. Retrieved 5 June 2020.
- Yan VC, Muller FL (14 May 2020). "Gilead should ditch remdesivir and focus on its simpler and safer ancestor". Statnews.
- Westgate J (7 May 2020). "Vet science 'being ignored' in quest for COVID-19 drug". Vet Times. Retrieved 28 July 2020.
- GmbH AD. "Verwandtschaft ersten Grades: Remdesivir-Metabolit noch schärfere Waffe gegen Covid-19?". Pharmazeutische Zeitung online (in German).
- "Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)". ClinicalTrials.gov. 25 June 2021. Retrieved 18 October 2021.
- "Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)". ClinicalTrials.gov. 5 October 2020. Retrieved 18 October 2021.
- "Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)". ClinicalTrials.gov. 5 October 2020. Retrieved 18 October 2021.
- "A Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19". ClinicalTrials.gov. Retrieved 10 September 2020.
- "The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)". ClinicalTrials.gov. Retrieved 10 September 2020.
- "Oral drug blocks SARS-CoV-2 transmission". medicalxpress.com. Retrieved 16 January 2021.
- Cox RM, Wolf JD, Plemper RK (January 2021). "Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets". Nature Microbiology. 6 (1): 11–18. doi:10.1038/s41564-020-00835-2. PMC 7755744. PMID 33273742.
- Covid antiviral pill can halve risk of hospitalisation BBC
- Covid antiviral pill halves hospitalisations and deaths, maker says The Guardian
- Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, et al. (May 2020). "Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs". Antimicrobial Agents and Chemotherapy. American Society for Microbiology. 64 (7). doi:10.1128/aac.00819-20. PMC 7318052. PMID 32366720. Lay summary.
Drug repositioning is the only feasible option to address the COVID‑19 global challenge immediately. We screened a panel of 48 FDA-approved drugs against SARS-CoV-2 which were pre-selected by an assay of SARS-CoV and identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low micromolar IC50s and in particular, two FDA-approved drugs – niclosamide and ciclesonide – were notable in some respects.
- Morse JS, Lalonde T, Xu S, Liu WR (March 2020). "Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV". ChemBioChem. 21 (5): 730–38. doi:10.1002/cbic.202000047. PMC 7162020. PMID 32022370.
- Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. (March 2020). "Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases". ACS Central Science. 6 (3): 315–31. doi:10.1021/acscentsci.0c00272. PMC 7094090. PMID 32226821.
- Ramajayam R, Tan KP, Liang PH (October 2011). "Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery". Biochemical Society Transactions. 39 (5): 1371–75. doi:10.1042/BST0391371. PMID 21936817.
- Tao, Kaiming; Tzou, Philip L.; Nouhin, Janin; Bonilla, Hector; Jagannathan, Prasanna; Shafer, Robert W. (28 July 2021). "SARS-CoV-2 Antiviral Therapy". Clinical Microbiology Reviews: e0010921. doi:10.1128/CMR.00109-21. PMC 8404831. PMID 34319150. S2CID 236472654.
- Zhang Y, Tang LV (January 2021). "Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication". J Proteome Res. 20 (1): 49–59. doi:10.1021/acs.jproteome.0c00526. PMC 7770889. PMID 33347311.
- Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P (September 2020). "Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis". Virol J. 17 (1): 141. doi:10.1186/s12985-020-01412-z. PMC 7512218. PMID 32972430.
- "Japanese flu drug 'clearly effective' in treating coronavirus, says China". 18 March 2020.
- "Coronavirus: Japanese anti-viral drug effective in treating patients, Chinese official says". The Independent.
- "Which Covid-19 drugs work best?". MIT Technology Review.
- "Coronavirus, il Veneto sperimenta l'antivirale giapponese Favipiravir. Ma l'Aifa: "Ci sono scarse evidenze scientifiche su efficacia"". Il Fatto Quotidiano (in Italian). 22 March 2020. Retrieved 23 March 2020.
- "AIFA precisa, uso favipiravir per COVID-19 non autorizzato in Europa e USA, scarse evidenze scientifiche sull'efficacia". aifa.gov.it (in Italian). Retrieved 23 March 2020.
- "Russian Ministry of Health approves the first COVID-19 drug Avifavir produced by JV of RDIF and ChemRar". RDIF. 30 May 2020. Retrieved 31 May 2020.
- "Russian Health Ministry approves anti-coronavirus drug Avifavir". BNN Bloomberg. 31 May 2020. Retrieved 31 May 2020.
- "Russia plans coronavirus vaccine clinical trials in two weeks". Reuters. 30 May 2020. Retrieved 31 May 2020.
- "Glenmark's FabiFlu approved for coronavirus treatment in India, costs Rs 103 per tablet". India Today. 20 June 2020. Retrieved 30 June 2020.
- Swift, Rocky (18 February 2021). Feast; Lincoln (eds.). "Fujifilm's Avigan shows no significant benefit on COVID-19 mortality: study". Reuters. Tokyo. Retrieved 25 April 2021.
- Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R (26 May 2021). "The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials". Scientific Reports. 11 (1): 11022. Bibcode:2021NatSR..1111022H. doi:10.1038/s41598-021-90551-6. ISSN 2045-2322. PMC 8155021. PMID 34040117.
- Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. (March 2020). "Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors". Science. 368 (6489): 409–12. Bibcode:2020Sci...368..409Z. doi:10.1126/science.abb3405. PMC 7164518. PMID 32198291.
- Kupferschmidt K, Cohen J (22 March 2020). "WHO launches global megatrial of the four most promising coronavirus treatments". Science Magazine. doi:10.1126/science.abb8497. S2CID 216325781. Retrieved 27 March 2020.
- Mullard A (April 2020). "Flooded by the torrent: the COVID-19 drug pipeline". Lancet. 395 (10232): 1245–46. doi:10.1016/S0140-6736(20)30894-1. PMC 7162641. PMID 32305088.
- Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (March 2020). "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19". The New England Journal of Medicine. 382 (19): 1787–99. doi:10.1056/nejmoa2001282. PMC 7121492. PMID 32187464.
- "Antiviral Drug Combo Ineffective Vs. Coronavirus". WebMD. 20 March 2020.
- Brown J (20 March 2020). "Colorado researchers are racing to find an antiviral drug that could save people with the new coronavirus".
- Devlin H, Sample I (19 March 2020). "What are the prospects for a COVID-19 treatment?". The Guardian.
- "No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in Recovery" (PDF). Recovery Trial: Statement from the Chief Investigators. 29 June 2020. Retrieved 30 June 2020.
- Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, Palfreeman A, Raw J, Elmahi E, Prudon B, Green C, et al. (Recovery Collaborative Group) (October 2020). "Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (Recovery): a randomised, controlled, open-label, platform trial". Lancet. 396 (10259): 1345–52. doi:10.1016/S0140-6736(20)32013-4. PMC 7535623. PMID 33031764. S2CID 222135901.
- Bagheri M, Niavarani A (October 2020). "Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding". Journal of Biomolecular Structure & Dynamics: 1–10. doi:10.1080/07391102.2020.1830854. PMID 33030105. S2CID 222217607.
- "Veklury EPAR". European Medicines Agency (EMA). 23 June 2020. Archived from the original on 18 March 2021. Retrieved 6 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "Gilead Announces Approval of Veklury (remdesivir) in Japan for Patients With Severe COVID-19" (Press release). Gilead Sciences. 7 May 2020. Archived from the original on 26 June 2020. Retrieved 25 June 2020 – via Business Wire.
- Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. (April 2020). "Current pharmacological treatments for COVID-19: What's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. eISSN 1476-5381. PMC 7264618. PMID 32329520.
- "Remdesivir". Drugs.com. 20 April 2020. Archived from the original on 16 April 2020. Retrieved 30 April 2020.
- Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A (July 2020). "Pharmacotherapy in COVID-19; A narrative review for emergency providers". The American Journal of Emergency Medicine. 38 (7): 1488–1493. doi:10.1016/j.ajem.2020.04.035. eISSN 0735-6757. PMC 7158837. PMID 32336586.
- "U.S. Food and Drug Administration Approves Gilead's Antiviral Veklury (remdesivir) for Treatment of COVID-19". Gilead Sciences, Inc. 22 October 2020. Archived from the original on 23 October 2020. Retrieved 23 October 2020.
- World Health Organization (2021). Therapeutics and COVID-19: living guideline, 6 July 2021 (Report). World Health Organization (WHO). hdl:10665/342368. WHO/2019-nCoV/therapeutics/2021.2. Lay summary.
- Stephens B (18 April 2020). "The Story of Remdesivir". The New York Times. p. A23. Archived from the original on 22 May 2020. Retrieved 11 May 2020.
- Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (March 2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–5. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMC 5551389. PMID 26934220.
- Kupferschmidt K, Cohen J (22 March 2020). "WHO launches global megatrial of the four most promising coronavirus treatments". Science Magazine. doi:10.1126/science.abb8497. S2CID 216325781. Archived from the original on 14 September 2020. Retrieved 27 March 2020.
- "Fact Sheet for Patients And Parent/Caregivers Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19)" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original on 16 May 2020. Retrieved 8 May 2020.
- Yan VC, Muller FL (14 May 2020). "Gilead should ditch remdesivir and focus on its simpler and safer ancestor". Stat. Boston Globe Media Partners. Archived from the original on 12 June 2021. Retrieved 5 July 2020.
- "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Archived from the original on 18 January 2021. Retrieved 17 January 2021. This article incorporates text from this source, which is in the public domain.
- Zumla A, Rao M, Wallis RS, Kaufmann SH, Rustomjee R, Mwaba P, et al. (April 2016). "Host-directed therapies for infectious diseases: current status, recent progress, and future prospects". The Lancet. Infectious Diseases (review). 16 (4): e47–63. doi:10.1016/S1473-3099(16)00078-5. PMC 7164794. PMID 27036359.
- Sourimant, Julien; Aggarwal, Megha; Plemper, Richard K (August 2021). "Progress and pitfalls of a year of drug repurposing screens against COVID-19". Current Opinion in Virology. 49: 183–193. doi:10.1016/j.coviro.2021.06.004. PMC 8214175. PMID 34218010.
- Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. (March 2020). "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro". Cell Research. 30 (3): 269–271. doi:10.1038/s41422-020-0282-0. PMC 7054408. PMID 32020029.
- Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. (March 2020). "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial". International Journal of Antimicrobial Agents. 56 (1): 105949. doi:10.1016/j.ijantimicag.2020.105949. PMC 7102549. PMID 32205204.
- Weston S, Coleman CM, Haupt R, Logue J, Matthews K, Li Y, et al. (October 2020). "Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo". J Virol. 94 (21). doi:10.1128/JVI.01218-20. PMC 7565640. PMID 32817221.
- "ФМБА России: доказана противовирусная активность "Мефлохина" в отношении возбудителя COVID-19" (in Russian). Federal Biomedical Agency. 10 April 2020. Retrieved 11 April 2020.
- Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (April 2020). "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro". Antiviral Research. 178: 104787. doi:10.1016/j.antiviral.2020.104787. PMC 7129059. PMID 32251768.
- "Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection". ClinicalTrials.gov. Retrieved 10 September 2020.
- "Chloroquine or Hydroxychloroquine". COVID-19 Treatment Guidelines. National Institutes of Health. Retrieved 14 February 2021.
- "Coronavirus (COVID-19) Update: Daily Roundup March 30, 2020". FDA. 30 March 2020.
- Smit M, Marinosci A, Agoritsas T, Calmy A (April 2021). "Prophylaxis for COVID-19: a systematic review". Clinical Microbiology and Infection (Systematic review). 27 (4): 532–537. doi:10.1016/j.cmi.2021.01.013. PMC 7813508. PMID 33476807.
- Meyerowitz EA, Vannier AG, Friesen MG, Schoenfeld S, Gelfand JA, Callahan MV, et al. (May 2020). "Rethinking the role of hydroxychloroquine in the treatment of COVID-19". FASEB Journal. 34 (5): 6027–6037. doi:10.1096/fj.202000919. PMC 7267640. PMID 32350928.
- "Assessment of Evidence for COVID-19-Related Treatments: Updated 4/3/2020". American Society of Health-System Pharmacists. Retrieved 7 April 2020.
- Yazdany J, Kim AH (June 2020). "Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know". Annals of Internal Medicine. 172 (11): 754–755. doi:10.7326/M20-1334. PMC 7138336. PMID 32232419.
- "Information for clinicians on therapeutic options for COVID-19 patients". US Centers for Disease Control and Prevention. 21 March 2020. Retrieved 22 March 2020.
- Hinton DM (28 March 2020). "Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 30 March 2020.
- "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. 11 February 2020. Retrieved 9 April 2020.
- Kalil AC (May 2020). "Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics". JAMA. 323 (19): 1897–1898. doi:10.1001/jama.2020.4742. PMID 32208486.
- "FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems". U.S. Food and Drug Administration (FDA). 24 April 2020.
- Mulier T (17 June 2020). "Hydroxychloroquine halted in WHO-sponsored COVID-19 trials". Bloomberg. Retrieved 17 June 2020.
- "No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19". Recovery Trial, Nuffield Department of Population Health, University of Oxford, UK. 5 June 2020. Retrieved 7 June 2020.
- "Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine". U.S. Food and Drug Administration (FDA) (Press release). 15 June 2020. Retrieved 15 June 2020.
- Berkeley Lovelace Jr (15 June 2020). "FDA revokes emergency use of hydroxychloroquine". CNBC.
- "Frequently Asked Questions on the Revocation of the Emergency Use Authorization for Hydroxychloroquine Sulfate and Chloroquine Phosphate" (PDF). U.S. Food and Drug Administration (FDA). 15 June 2020. Retrieved 15 June 2020.
- "Clinical Management Protocol for Covid-19 (in Adults)" (PDF). Ministry of Health and Family Welfare. 24 May 2021. "Health ministry issues revised clinical management protocols for Covid-19 amid spurt in cases". Times of India. Press Trust of India. 13 June 2021. Retrieved 10 July 2021.
- U.S. FDA [@US_FDA] (21 August 2021). "You are not a horse. You are not a cow. Seriously, y'all. Stop it" (Tweet). Archived from the original on 21 August 2021 – via Twitter.
- Heidary F, Gharebaghi R (September 2020). "Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen". The Journal of Antibiotics. 73 (9): 593–602. doi:10.1038/s41429-020-0336-z. PMC 7290143. PMID 32533071.
- Şimşek Yavuz S, Ünal S (April 2020). "Antiviral treatment of COVID-19". Turkish Journal of Medical Sciences. 50 (SI-1): 611–9. doi:10.3906/sag-2004-145. PMC 7195979. PMID 32293834.
- Bray M, Rayner C, Noël F, Jans D, Wagstaff K (June 2020). "Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses". Antiviral Research. 178: 104805. doi:10.1016/j.antiviral.2020.104805. PMC 7172803. PMID 32330482.
- López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. (4 March 2021). "Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19". JAMA. 325 (14): 1426–35. doi:10.1001/jama.2021.3071. ISSN 0098-7484. PMC 7934083. PMID 33662102.
- Yang SN, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, Jans DA (May 2020). "The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer" (PDF). Antiviral Research. 177: 104760. doi:10.1016/j.antiviral.2020.104760. PMID 32135219. S2CID 212565030.
- Garegnani LI, Madrid E, Meza N (22 April 2021). "Misleading clinical evidence and systematic reviews on ivermectin for COVID-19". BMJ Evidence-Based Medicine. doi:10.1136/bmjebm-2021-111678. ISSN 2515-446X. PMID 33888547.
- "Why You Should Not Use Ivermectin to Treat or Prevent COVID-19". U.S. Food and Drug Administration (FDA). 5 March 2021. Retrieved 5 March 2021.
- "New Mexico links 2 deaths to ivermectin misuse". 5 March 2021. Retrieved 22 October 2021.
- Schraer, Rachel (23 June 2021). "Covid: Ivermectin to be studied as possible treatment in UK". BBC News. Retrieved 23 June 2021.
- "COVID-19 Therapeutics Prioritized for Testing in Clinical Trials". National Institutes of Health. 21 July 2020. Retrieved 27 June 2021.
- Bartoszko JJ, Siemieniuk RA, Kum E, Qasim A, Zeraatkar D, et al. (April 2021). "Prophylaxis against covid-19: living systematic review and network meta-analysis". BMJ (Systematic review). 373: n949. doi:10.1136/bmj.n949. PMC 8073806. PMID 33903131.
- Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV (28 June 2021). "Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials". Clinical Infectious Diseases. doi:10.1093/cid/ciab591. ISSN 1058-4838. PMC 8394824. PMID 34181716.
- Popp M, Stegemann M, Metzendorf M, Gould S, Kranke P, Meybohm P, et al. (28 July 2021). "Ivermectin for preventing and treating COVID-19". Cochrane Database of Systematic Reviews. 2021 (8): CD015017. doi:10.1002/14651858.cd015017.pub2. ISSN 1465-1858. PMC 8406455. PMID 34318930.
- "Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns". The Guardian. 15 July 2021. Retrieved 27 September 2021.
- Piller C, Servick K (4 June 2020). "Two elite medical journals retract coronavirus papers over data integrity questions". Science. Retrieved 5 June 2020.
- "Surgisphere Sows Confusion About Another Unproven COVID-19 Drug". The Scientist Magazine®. 16 June 2020. Retrieved 9 July 2020.
- Garegnani LI, Madrid E, Meza N (April 2021). "Misleading clinical evidence and systematic reviews on ivermectin for COVID-19". BMJ Evidence-Based Medicine. doi:10.1136/bmjebm-2021-111678. PMID 33888547.
- Molento MB (December 2021). "Ivermectin against COVID-19: The unprecedented consequences in Latin America". One Health. 13: 100250. doi:10.1016/j.onehlt.2021.100250. PMC 8050401. PMID 33880395.
- Gorski DH (15 April 2021). "Ivermectin is the new hydroxychloroquine". Science-Based Medicine.
- "Merck Statement on Ivermectin use During the COVID-19 Pandemic". Merck. 4 February 2021.
- "EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials" (Press release). European Medicines Agency. 22 March 2021.
- "The COVID-19 Treatment Guidelines Panel's Statement on the Use of Ivermectin for the Treatment of COVID-19". National Institutes of Health. 14 January 2020.
- Wadvalla BA (April 2021). "Covid-19: Ivermectin's politicisation is a warning sign for doctors turning to orphan treatments". BMJ. 373: n747. doi:10.1136/bmj.n747. PMID 33795225. S2CID 232484313.
- "WHO advises that ivermectin only be used to treat COVID-19 within clinical trials". World Health Organisation. 31 March 2021.
- Quintanilha, Dayana de Oliveira (13 July 2020). "Anvisa se manifesta contra o uso da ivermectina na Covid-19" [Anvisa speaks out against the use of ivermectin in Covid-19]. PEBMED (in Portuguese).
- "Atualizações e Recomendações sobre a Covid-19" [Updates and recommendations on Covid-19] (PDF) (in Portuguese). Sociedade Brasileira de Infectologia. 9 December 2020.
- "Posicionamento da Sociedade Brasileira de Pneumologia e Tisiologia Sobre o Colapso em Manaus e Tratamento Preventivo e Precoce da Covid-19" [Brazilian Thoracic Society Position Statement on the Collapse in Manaus and the Preventive and Early Treatment of Covid-19] (in Portuguese). Sociedade Brasileira de Pneumologia e Tisiologia. 17 January 2021. Retrieved 18 January 2021.
- Mega ER (October 2020). "Latin America's embrace of an unproven COVID treatment is hindering drug trials". Nature. 586 (7830): 481–2. Bibcode:2020Natur.586..481M. doi:10.1038/d41586-020-02958-2. PMID 33077974.
- Molento MB (December 2020). "COVID-19 and the rush for self-medication and self-dosing with ivermectin: A word of caution". One Health. Elsevier BV. 10: 100148. doi:10.1016/j.onehlt.2020.100148. PMC 7313521. PMID 32632377.
- "The rise and fall of a coronavirus 'miracle cure'". Politico. 30 March 2021. Retrieved 31 May 2021.
- Ferrer, Angélica (22 January 2021). "Médicos en CDMX suministran ivermectina y azitromicina para tratar pacientes con COVID-19". El Financiero (in Spanish). Retrieved 18 July 2021.
- Andina (13 October 2020). "Covid-19: Minsa aprueba resolución que deja sin efecto el uso de tres medicamentos" (in Spanish). Agencia Peruana de Noticias.
- "Ivermectina vuelve a ser incluida en tratamiento covid-19" (in Spanish). Extra. 22 January 2021.
- Mishra, Manas (13 May 2021). "Indian states turn to anti-parasitic drug to fight COVID-19 against WHO advice". Reuters. Retrieved 30 May 2021.
- "Fact check: No link between India's falling COVID-19 cases and hydroxychloroquine". USA Today. 21 May 2021. Retrieved 25 May 2021.
- Mordani, Sneha. "DGHS drops Ivermectin, Doxycycline from Covid-19 treatment; ICMR rules unchanged". India Today. Retrieved 18 July 2021.
- Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (May 2020). "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy". Journal of Thrombosis and Haemostasis. 18 (5): 1094–9. doi:10.1111/jth.14817. PMID 32220112.
- "Medicines usable for treatment of COVID-19 disease". Italian Medicines Agency. Retrieved 29 March 2021.
- "Low molecular weight heparins in the treatment of adult patients with COVID-19". AIFA Italian Medicines Agencty. 24 November 2020.
- Weintraub A. "How COVID-19 could be crippled by an age-old blood thinner". Fierce Biotech. Retrieved 22 July 2020.
- "Coronavirus, al via studio su eparina per 300 pazienti". Adnkronos. Retrieved 15 April 2020.
- Rogosnitzky M, Berkowitz E, Jadad AR (May 2020). "Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point". JMIR Public Health and Surveillance. 6 (2): e19199. doi:10.2196/19199. PMC 7224168. PMID 32374264.
- "Chinese Clinical Trial Register (ChiCTR) – The world health organization international clinical trials registered organization registered platform". www.chictr.org.cn.
- "EMA starts evaluating the use of Kineret in adult COVID-19 patients at increased risk severe respiratory failure". European Medicines Agency (EMA) (Press release). 16 July 2021. Retrieved 20 July 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "WHO officials enroll first patients from Norway and Spain in 'historic' coronavirus drug trial". CNBC. 27 March 2020.
- "REMAP-CAP Trial". REMAP-CAP.
- "Traumakine to be a part of WHO's Solidarity trial investigating potential COVID-19 treatments". Faron Pharmaceuticals (Press release). 27 April 2020. Retrieved 8 May 2020.
- "Dexamethasone". The American Society of Health-System Pharmacists. Archived from the original on 31 August 2017. Retrieved 29 July 2015.
- Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, et al. (March 2020). "Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial". The Lancet. Respiratory Medicine. 8 (3): 267–276. doi:10.1016/s2213-2600(19)30417-5. PMID 32043986.
Early administration of dexamethasone could reduce duration of mechanical ventilation and overall mortality in patients with established moderate-to-severe ARDS.
- Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. (October 2020). "Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis". JAMA. 324 (13): 1330–41. doi:10.1001/jama.2020.17023. PMC 7489434. PMID 32876694.
- "Corticosteroids for COVID-19", Living Guidance, WHO, 2 September 2020, retrieved 2 September 2020
- "Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19". University of Oxford. 16 June 2020. Retrieved 16 June 2020.
- "Steroid drug hailed as 'breakthrough' for seriously ill COVID-19 patients". Reuters. 17 June 2020. Retrieved 18 June 2020.
- Ducharme J. "A Low-Cost Steroid Shows Promise for Treating COVID-19. But Take the News With a Grain of Salt". Time. Retrieved 18 June 2020.
- Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B (22 June 2020). Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report (Report). doi:10.1101/2020.06.22.20137273. S2CID 219965377.
- Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. (July 2020). "Dexamethasone in Hospitalized Patients with Covid-19 – Preliminary Report". The New England Journal of Medicine. 384 (8): 693–704. doi:10.1056/NEJMoa2021436. PMC 7383595. PMID 32678530.
- "Corticosteroids (Including Dexamethasone)". COVID-19 Treatment Guidelines. National Institutes of Health. Retrieved 12 July 2020.
- "Q&A: Dexamethasone and COVID-19". World Health Organization (WHO). Retrieved 12 July 2020.
- "COVID-19 Guideline, Part 1: Treatment and Management". Infectious Diseases Society of America. Retrieved 22 July 2020.
Recommendation 4. Among hospitalized patients with severe* COVID-19, the IDSA guideline panel suggests glucocorticoids rather than no glucocorticoids. (Conditional recommendation, Moderate certainty of evidence)
Remark: Dexamethasone 6 mg IV or PO for 10 days (or until discharge if earlier) or equivalent glucocorticoid dose may be substituted if dexamethasone unavailable. Equivalent total daily doses of alternative glucocorticoids to dexamethasone 6 mg daily are methylprednisolone 32 mg and prednisone 40 mg.
Recommendation 5. Among hospitalized patients with COVID-19 without hypoxemia requiring supplemental oxygen, the IDSA guideline panel suggests against the use of glucocorticoids. (Conditional recommendation, Low certainty of evidence)
- "EMA starts review of dexamethasone for treating adults with COVID-19 requiring respiratory support". European Medicines Agency (EMA) (Press release). 24 July 2020. Retrieved 27 July 2020. Text was copied from this source, copyrighted by the European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- World Health Organization (2020). Corticosteroids for COVID-19: living guidance, 2 September 2020 (Report). World Health Organization. hdl:10665/334125. WHO/2019-nCoV/Corticosteroids/2020.1. Lay summary.
- "EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation". European Medicines Agency (EMA) (Press release). 18 September 2020. Retrieved 21 September 2020. Text was copied from this source, which is copyrighted by the European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. (October 2020). "Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis". JAMA. 324 (13): 1330–41. doi:10.1001/jama.2020.17023. PMC 7489434. PMID 32876694.
- "A parasitic infection that can turn fatal with administration of corticosteroids". WHO. 17 December 2021.
- Ramakrishnan S, Nicolau DV, Langford B, Mahdi M, Jeffers H, Mwasuku C, Krassowska K, Fox R, Binnian I, Glover V, Bright S, Butler C, Cane JL, Halner A, Matthews PC, Donnelly LE, Simpson JL, Baker JR, Fadai NT, Peterson S, Bengtsson T, Barnes PJ, Russell RE, Bafadhel M (April 2021). "Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial". The Lancet. Respiratory Medicine. 9 (7): 763–772. doi:10.1016/S2213-2600(21)00160-0. PMC 8040526. PMID 33844996.
- Agusti A, Torres F, Faner R (April 2021). "Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19". The Lancet. Respiratory Medicine (Commentary). 9 (7): 682–683. doi:10.1016/S2213-2600(21)00171-5. PMC 8040539. PMID 33844998.
- "CAS-ViewAlert". www.cas.mhra.gov.uk. Retrieved 16 April 2021.
- Deokar K, Agarwal M, Dutt N, Chauhan N, Niwas R, Shadrach BJ, Chawla G (2021). "A review of Ciclesonide in COVID-19. Still a long way to go". Advances in Respiratory Medicine. 89 (1): 79–81. doi:10.5603/ARM.a2020.0173. PMID 33471354.
- Abobaker A, Alzwi A, Alraied AH (December 2020). "Overview of the possible role of vitamin C in management of COVID-19". Pharmacological Reports. 72 (6): 1517–28. doi:10.1007/s43440-020-00176-1. PMC 7592143. PMID 33113146.
- "Search of: vitamin C | Recruiting, Completed Studies | COVID-19". clinicaltrials.gov. Retrieved 27 February 2021.
- Martineau AR, Forouhi NG (September 2020). "Vitamin D for COVID-19: a case to answer?". The Lancet. Diabetes & Endocrinology. 8 (9): 735–6. doi:10.1016/S2213-8587(20)30268-0. PMC 7398646. PMID 32758429.
- "Vitamin D". Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health (NIH). 17 July 2020. Retrieved 22 February 2021. This article incorporates text from this source, which is in the public domain.
- COVID-19 rapid guideline: vitamin D (PDF) (Technical report). National Institute for Health and Care Excellence (NICE). December 2020. ISBN 978-1-4731-3942-8. NG187. Retrieved 22 February 2021.
- Damascena, Alialdo Dantas; Azevedo, Laylla Mirella Galvão; Oliveira, Tarcio de Almeida; Santana, Jerusa da Mota; Pereira, Marcos (12 August 2021). "Addendum to vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis". Critical Reviews in Food Science and Nutrition: 1–6. doi:10.1080/10408398.2021.1951652. ISSN 1549-7852. PMID 34384300. S2CID 236997712.
- Kazemi A, Mohammadi V, Aghababaee SK, Golzarand M, Clark CC, Babajafari S (March 2021). "Association of Vitamin D Status with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-analysis". Advances in Nutrition. 12 (5): 1636–1658. doi:10.1093/advances/nmab012. PMC 7989595. PMID 33751020.
- Petrelli F, Luciani A, Perego G, Dognini G, Colombelli PL, Ghidini A (March 2021). "Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies". The Journal of Steroid Biochemistry and Molecular Biology. 211: 105883. doi:10.1016/j.jsbmb.2021.105883. PMC 7997262. PMID 33775818.
- Bassatne A, Basbous M, Chakhtoura M, Zein OE, Rahme M, Fuleihan GE (March 2021). "The link between COVID-19 and Vitamin D (VIVID): a systematic review and meta-analysis". Metabolism (Systematic review). 119: 154753. doi:10.1016/j.metabol.2021.154753. PMC 7989070. PMID 33774074.
- Evidence reviews for the use of vitamin D supplementation as prevention and treatment of COVID-19 (PDF) (Report). National Institute for Health and Care Excellence (NICE). December 2020.
- "International clinical trials assessing vitamin D in people with COVID-19". ClinicalTrials.gov. Retrieved 11 June 2021.
- Quesada-Gomez JM, Entrenas-Castillo M, Bouillon R (September 2020). "Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166". The Journal of Steroid Biochemistry and Molecular Biology. 202: 105719. doi:10.1016/j.jsbmb.2020.105719. PMC 7289092. PMID 32535032.
- Shah K, Saxena D, Mavalankar D (January 2021). "Vitamin D supplementation, COVID-19 & Disease Severity: A meta-analysis". QJM : Monthly Journal of the Association of Physicians. 114 (3): 175–181. doi:10.1093/qjmed/hcab009. PMC 7928587. PMID 33486522.
- Stroehlein JK, Wallqvist J, Iannizzi C, Mikolajewska A, Metzendorf MI, Benstoem C, et al. (May 2021). "Vitamin D supplementation for the treatment of COVID-19: a living systematic review". The Cochrane Database of Systematic Reviews. 2021 (5): CD015043. doi:10.1002/14651858.CD015043. PMC 8406457. PMID 34029377. S2CID 235202971.
- Cesareo R, Falchetti A, Attanasio R, Tabacco G, Naciu AM, Palermo A (May 2019). "Hypovitaminosis D: Is It Time to Consider the Use of Calcifediol?". Nutrients (Review). 11 (5): 1016. doi:10.3390/nu11051016. PMC 6566727. PMID 31064117.
- Ansede M (3 April 2020). "Doscientos enfermos probarán un fármaco que ha bloqueado el coronavirus en minirriñones humanos". El País (in Spanish). Retrieved 3 April 2020.
- "Apeiron Biologics moves forward with APN01 for treatment of COVID-19". www.thepharmaletter.com. Retrieved 3 April 2020.
- "Coronavirus: Scientists could repurpose drugs to treat infection". Medical News Today. 28 February 2020. Retrieved 20 March 2020.
- "Existing Drugs May Offer a First-Line Treatment for Coronavirus Outbreak". Global Health News Wire. Retrieved 20 March 2020.
- Baron SA, Devaux C, Colson P, Raoult D, Rolain JM (April 2020). "Teicoplanin: an alternative drug for the treatment of COVID-19?". International Journal of Antimicrobial Agents. 55 (4): 105944. doi:10.1016/j.ijantimicag.2020.105944. PMC 7102624. PMID 32179150.
- Andersen PI, Ianevski A, Lysvand H, Vitkauskiene A, Oksenych V, Bjørås M, et al. (April 2020). "Discovery and development of safe-in-man broad-spectrum antiviral agents". International Journal of Infectious Diseases. 93: 268–276. doi:10.1016/j.ijid.2020.02.018. PMC 7128205. PMID 32081774.
- "Amid Ongoing COVID-19 Pandemic, Governor Cuomo Accepts Recommendation of Army Corps of Engineers for Four Temporary Hospital Sites in New York". governor.ny.gov. 22 March 2020.
- "Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19" (Press release). Revive Therapeutics Ltd. 31 July 2020. Retrieved 5 August 2020 – via GlobeNewswire.
- Favalli, Ennio G; Biggioggero, Martina; Maioli, Gabriella; Caporali, Roberto (September 2020). "Baricitinib for COVID-19: a suitable treatment?". The Lancet. Infectious Diseases. 20 (9): 1012–13. doi:10.1016/S1473-3099(20)30262-0. ISSN 1473-3099. PMC 7270794. PMID 32251638.
- "Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19" (Press release). FDA. 19 November 2020. Retrieved 4 December 2020.
- "Fact Sheet for Healthcare Providers Emergency Use Authorization (EUA) of Baricitinib" (PDF). Indianapolis: Ely Lilly and Company. 19 November 2020. Retrieved 4 December 2020.
- "EMA starts evaluating use of Olumiant in hospitalised COVID-19 patients requiring supplemental oxygen" (Press release). European Medicines Agency (EMA). 29 April 2021. Retrieved 29 April 2021.
- "Baricitinib Emergency Use Authorization (EUA)" (PDF). U.S. Food and Drug Administration (FDA). July 2021.
- "Fact Sheet for Baricitinib Emergency Use Authorization (EUA)" (PDF). U.S. Food and Drug Administration (FDA). July 2021.
- "Coronavirus (COVID-19) Update: July 30, 2021". U.S. Food and Drug Administration (FDA) (Press release). 30 July 2021. Retrieved 30 July 2021. This article incorporates text from this source, which is in the public domain.
- Firth A, Prathapan P (1 January 2021). "Broad-spectrum therapeutics: A new antimicrobial class". Current Research in Pharmacology and Drug Discovery. 2: 100011. doi:10.1016/j.crphar.2020.100011.
- Firth A, Prathapan P (December 2020). "Azithromycin: The First Broad-spectrum Therapeutic". European Journal of Medicinal Chemistry. 207: 112739. doi:10.1016/j.ejmech.2020.112739. PMC 7434625. PMID 32871342.
- "Biodefense Strategic Plan | NIH: National Institute of Allergy and Infectious Diseases". www.niaid.nih.gov. Retrieved 2 February 2021.
- "NIH funds development of new broad-spectrum therapeutics". National Institutes of Health (NIH). 18 September 2015. Retrieved 2 February 2021.
- "New York clinical trial quietly tests heartburn remedy against coronavirus". Science. 26 April 2020.
- ICIRadio-Canadaca ZS. "Début d'une étude clinique pour tester un médicament contre les effets de la COVID-19 | Coronavirus". Radio-Canada.ca.
- "COLCORONA Clinical Trial | Stop COVID-19". Colcorona.
- Ehrlich A, Uhl S, Ioannidis K, Hofree M, tenOever BR, Nahmias Y (14 July 2020). "The SARS-CoV-2 Transcriptional Metabolic Signature in Lung Epithelium". SSRN 3650499.
- "Antiviral Drug Reduces COVID-19 Inflammation In 48 Hours – Israel Study".
- "Cholesterol Drug May Downgrade COVID-19 Threat - New Study". 29 July 2020.
- "LIBERATE Trial in COVID-19 (LIBERATE)". ClinicalTrials.gov. Retrieved 10 September 2020.
- "Coronavirus: Ibuprofen tested as a treatment". BBC. 3 June 2020. Retrieved 4 June 2020.
- Fink G, Orlova-Fink N, Schindler T, Grisi S, Ferrer AP, Daubenberger C, et al. (1 July 2020). "Inactivated trivalent influenza vaccine is associated with lower mortality among Covid-19 patients in Brazil (preprint)". medRxiv. doi:10.1101/2020.06.29.20142505. S2CID 220267530.
Covid-19 patients with recent influenza vaccination experience better health outcomes than non-vaccinated patients in Brazil.
- "Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma". ClinicalTrials.gov. 5 March 2020. Retrieved 10 September 2020.
- Ning, Qin (14 March 2020). "A Pilot Study of Sildenafil in COVID-19". ClinicalTrials.gov. Retrieved 10 September 2020.
- Banday AH, Shameem SA, Ajaz SJ (2020). "Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status". SLAS Discov. 25 (10): 1097–107. doi:10.1177/2472555220945281. PMID 32692266. S2CID 220671335.CS1 maint: multiple names: authors list (link)
- Cantini F, Goletti D, Petrone L, Najafi Fard S, Niccoli L, Foti R (October 2020). "Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review". Drugs. 80 (18): 1929–46. doi:10.1007/s40265-020-01421-w. PMC 7568461. PMID 33068263.
- Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. (July 2020). "A SARS-CoV-2 protein interaction map reveals targets for drug repurposing". Nature. 583 (7816): 459–68. Bibcode:2020Natur.583..459G. doi:10.1038/s41586-020-2286-9. PMC 7431030. PMID 32353859.
- Guy RK, DiPaola RS, Romanelli F, Dutch RE (May 2020). "Rapid repurposing of drugs for COVID-19". Science. 368 (6493): 829–30. Bibcode:2020Sci...368..829G. doi:10.1126/science.abb9332. PMID 32385101.
- Kotecha P, Light A, Checcucci E, Amparore D, Fiori C, Porpiglia F, Dasgupta P, Elhage O (October 2020). "Repurposing of drugs for Covid-19: a systematic review and meta-analysis". Panminerva Med. doi:10.23736/S0031-0808.20.04024-0. PMID 33073552.
- Lamontagne, François; Agoritsas, Thomas; Siemieniuk, Reed; Rochwerg, Bram; Bartoszko, Jessica; Askie, Lisa; et al. (2 March 2021). "A living WHO guideline on drugs to prevent covid-19". British Medical Journal. 372: n526. doi:10.1136/bmj.n526. ISSN 1756-1833. PMID 33649077. S2CID 232081225.
- McCreary EK, Pogue JM (April 2020). "Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options". Open Forum Infectious Diseases. 7 (4): ofaa105. doi:10.1093/ofid/ofaa105. PMC 7144823. PMID 32284951.
- Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. (July 2020). "Drug treatments for covid-19: living systematic review and network meta-analysis". BMJ. 370: m2980. doi:10.1136/bmj.m2980. PMC 7390912. PMID 32732190.
- Velasquez-Manoff M (11 August 2020). "How Covid Sends Some Bodies to War With Themselves". The New York Times.
- Zimmer C (30 April 2020). "Old Drugs May Find a New Purpose: Fighting the Coronavirus". The New York Times.
- "COVID-19 therapeutics tracker". Regulatory Affairs Professionals Society.
- "STAT's Covid-19 Drugs and Vaccines Tracker". Stat. 27 April 2020.
- "Coronavirus Drug and Treatment Tracker". The New York Times.
- "JHMI Clinical Recommendations for Available Pharmacologic Therapies for COVID-19". Johns Hopkins.
- World Health Organization (2021). Therapeutics and COVID-19: living guideline, 6 July 2021 (Report). World Health Organization (WHO). hdl:10665/342368. WHO/2019-nCoV/therapeutics/2021.2. Lay summary.